OAKVILLE, ON, Nov. 7, 2016 /PRNewswire/ - Concordia International Corp. (“Concordia” or the “Company”) (CXRX) (CXR.TO), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, today announced its financial and operational results for the three and nine months ended September 30, 2016. All financial references are in U.S. dollars unless otherwise noted.
